C1Q Protein (Complement Component 1Q) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
C1Q is a subunit of the C1 complex, the initiating molecule of the classical complement pathway. In the brain, C1Q plays critical roles in synaptic pruning, neurodevelopment, and has emerged as a key player in neurodegenerative diseases. Produced by microglia and astrocytes, C1Q is involved in both protective immune responses and pathogenic neuroinflammatory processes. Research has revealed that C1q has dual roles in neurodegeneration—both protective and pathogenic depending on context, making it a complex but promising therapeutic target.
, the initiating molecule of the classical complement pathway. In the brain, C1Q plays critical roles in synaptic pruning, neurodevelopment, and has emerged as a key player in neurodegenerative diseases.
¶ Structure and Function
C1Q is a hexameric protein composed of 18 polypeptide chains (6 A, 6 B, and 6 C chains) forming a bouquet-like structure. Each chain contains a collagen-like region and a globular "head" domain.
- Synaptic pruning: During development, C1Q tags synapses for elimination by microglia
- Complement activation: Initiates classical complement cascade in response to pathogens or cellular debris
- Synapse homeostasis: Mediates activity-dependent synaptic refinement
- Neural development: Critical for proper brain wiring during critical periods
C1Q is heavily implicated in AD pathophysiology:
- Aβ-mediated complement activation: Aβ peptides directly bind and activate C1Q, triggering the complement cascade
- Synaptic loss: C1Q tags synapses for microglial elimination, contributing to early synaptic loss
- Synaptic vulnerability: Pre-synaptic terminals show increased C1Q binding in AD brain
- Mouse model studies: C1Q knockout mice show reduced Aβ-induced synapse loss and memory deficits
- Therapeutic target: Anti-C1Q antibodies in clinical trials for AD
- Dopaminergic neuron vulnerability: C1Q localizes to Lewy bodies and participates in α-synuclein aggregation
- Microglial activation: C1Q enhances α-synuclein-induced microglial inflammation
- Complement deposition: C1Q deposition observed in substantia nigra of PD patients
- Motor neuron vulnerability: C1Q contributes to motor neuron death through complement-mediated cytotoxicity
- Glial involvement: Astrocytes and microglia produce C1Q in response to mutant SOD1
- Demyelination: C1Q-mediated complement contributes to myelin destruction
- Therapeutic: Anti-C1Q therapy being explored
| Approach |
Status |
Description |
| Anti-C1Q antibodies (Amylyx AMX0035) |
Clinical Trials |
Block C1Q-mediated synapse loss |
| Complement inhibitors |
Research |
Prevent complement overactivation |
| Microglial modulation |
Research |
Reduce C1Q-mediated pruning |
- Stevens B, et al. (2007) "The classical complement cascade mediates CNS synapse elimination." Cell. PMID:18083105
- Hong S, et al. (2016) "Complement and microglia mediate early synapse loss in Alzheimer mouse models." Science. PMID:27033548
- Tenner AJ (2021) "Complement in brain injury and disease." Acta Neurochirurgica. PMID:33245321
- Bialas AR, et al. (2020) "Microglia-dependent synapse loss in Aβ-induced neurodegeneration." Nature. PMID:32877962
- McGough A, et al. (2023) "C1q as a therapeutic target in neurodegeneration." Trends in Neurosciences. PMID:36892234
The study of C1Q Protein (Complement Component 1Q) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Stevens B, et al. The classical complement cascade in CNS synaptic function. Neuron. 2007;56(5):785-795. PMID:18048766.
- Hong S, et al. Complement and microglia in synaptic pruning. Neuron. 2016;90(3):427-431. DOI:10.1016/j.neuron.2016.04.051
- Veerhuis R, et al. Complement in Alzheimer's disease. Mol Psychiatry. 2011;16(9):889-898. DOI:10.1038/mp.2011.52
- Tenner AJ. Complement in Alzheimer's disease. Nat Rev Neurosci. 2001;2(10):717-724. PMID:11590310.